JiangXi Tianxin Pharmaceutical Co., Ltd. (SHA:603235)
China
· Delayed Price · Currency is CNY 26.35
-0.03 (-0.11%)
At close: Apr 29, 2026
SHA:603235 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 2,345 | 2,181 | 1,851 | 2,253 | 2,466 | Upgrade
|
| Other Revenue | - | 28 | 30.6 | 51.71 | 55.97 | Upgrade
|
| Revenue | 2,345 | 2,209 | 1,882 | 2,305 | 2,522 | Upgrade
|
| Revenue Growth (YoY) | 6.18% | 17.35% | -18.34% | -8.63% | 9.50% | Upgrade
|
| Cost of Revenue | 1,353 | 1,288 | 1,174 | 1,450 | 1,432 | Upgrade
|
| Gross Profit | 992.23 | 920.91 | 708.11 | 854.67 | 1,090 | Upgrade
|
| Selling, General & Admin | 218.12 | 177.02 | 169.21 | 174.88 | 140.19 | Upgrade
|
| Research & Development | 100.52 | 103.82 | 111.96 | 89.46 | 58.94 | Upgrade
|
| Other Operating Expenses | -15.78 | 17.86 | 19.81 | 21.97 | 22.77 | Upgrade
|
| Operating Expenses | 302.87 | 301.92 | 299.32 | 282.46 | 228.3 | Upgrade
|
| Operating Income | 689.36 | 619 | 408.79 | 572.21 | 862.11 | Upgrade
|
| Interest Expense | - | -2.48 | -2.1 | -6.93 | -12.67 | Upgrade
|
| Interest & Investment Income | 8.93 | 64.81 | 76.54 | 22.88 | 4.34 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 54.19 | 31.24 | 82.37 | -26.95 | Upgrade
|
| Other Non Operating Income (Expenses) | 23.98 | -1.25 | 0.32 | -1.74 | -1.61 | Upgrade
|
| EBT Excluding Unusual Items | 722.27 | 734.26 | 514.79 | 668.79 | 825.22 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 2.24 | - | 4.33 | -6.61 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.51 | -1.07 | -0.09 | -1.07 | -2.14 | Upgrade
|
| Asset Writedown | -17.34 | -0.61 | -0.19 | -0.86 | - | Upgrade
|
| Other Unusual Items | - | 36.95 | 50.66 | 54.57 | 56.91 | Upgrade
|
| Pretax Income | 704.42 | 771.77 | 565.17 | 725.76 | 873.37 | Upgrade
|
| Income Tax Expense | 112.84 | 120.55 | 89.32 | 103.64 | 129.49 | Upgrade
|
| Net Income | 591.58 | 651.22 | 475.85 | 622.12 | 743.89 | Upgrade
|
| Net Income to Common | 591.58 | 651.22 | 475.85 | 622.12 | 743.89 | Upgrade
|
| Net Income Growth | -9.16% | 36.85% | -23.51% | -16.37% | -16.14% | Upgrade
|
| Shares Outstanding (Basic) | 438 | 437 | 437 | 412 | 394 | Upgrade
|
| Shares Outstanding (Diluted) | 438 | 437 | 437 | 412 | 394 | Upgrade
|
| Shares Change (YoY) | 0.26% | 0.11% | 5.96% | 4.68% | -0.10% | Upgrade
|
| EPS (Basic) | 1.35 | 1.49 | 1.09 | 1.51 | 1.89 | Upgrade
|
| EPS (Diluted) | 1.35 | 1.49 | 1.09 | 1.51 | 1.89 | Upgrade
|
| EPS Growth | -9.40% | 36.70% | -27.82% | -20.11% | -16.00% | Upgrade
|
| Free Cash Flow | 48.68 | -567.3 | 193.61 | 346.11 | 603.13 | Upgrade
|
| Free Cash Flow Per Share | 0.11 | -1.30 | 0.44 | 0.84 | 1.53 | Upgrade
|
| Dividend Per Share | - | 0.680 | 0.500 | 0.710 | - | Upgrade
|
| Dividend Growth | - | 36.00% | -29.58% | - | - | Upgrade
|
| Gross Margin | 42.31% | 41.70% | 37.63% | 37.08% | 43.23% | Upgrade
|
| Operating Margin | 29.40% | 28.03% | 21.72% | 24.83% | 34.18% | Upgrade
|
| Profit Margin | 25.23% | 29.49% | 25.29% | 26.99% | 29.49% | Upgrade
|
| Free Cash Flow Margin | 2.08% | -25.69% | 10.29% | 15.02% | 23.91% | Upgrade
|
| EBITDA | 875.78 | 770.02 | 544.64 | 695.81 | 969.57 | Upgrade
|
| EBITDA Margin | 37.35% | 34.87% | 28.94% | 30.19% | 38.44% | Upgrade
|
| D&A For EBITDA | 186.42 | 151.02 | 135.85 | 123.6 | 107.46 | Upgrade
|
| EBIT | 689.36 | 619 | 408.79 | 572.21 | 862.11 | Upgrade
|
| EBIT Margin | 29.40% | 28.03% | 21.72% | 24.83% | 34.18% | Upgrade
|
| Effective Tax Rate | 16.02% | 15.62% | 15.80% | 14.28% | 14.83% | Upgrade
|
| Revenue as Reported | - | 2,209 | 1,882 | 2,305 | 2,522 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.